MARKET

GERN

GERN

Geron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.790
-0.060
-3.24%
After Hours: 1.800 +0.01 +0.56% 19:01 10/28 EDT
OPEN
1.810
PREV CLOSE
1.850
HIGH
1.850
LOW
1.780
VOLUME
2.05M
TURNOVER
--
52 WEEK HIGH
2.400
52 WEEK LOW
0.7500
MARKET CAP
555.74M
P/E (TTM)
-4.8067
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Geron Announces Publication Of IMerge Phase 2 Data In Journal Of Clinical Oncology
Results support ongoing IMerge Phase 3 clinical trial Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in
Benzinga · 7h ago
Geron (GERN) Expected to Beat Earnings Estimates: Should You Buy?
Zacks · 11h ago
Is Geron Corporation (NASDAQ:GERN) Popular Amongst Institutions?
The big shareholder groups in Geron Corporation (NASDAQ:GERN) have power over the company. Large companies usually...
Simply Wall St. · 5d ago
Geron Secures Loan Facility for Up to $75 Million
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 million with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank (SVB). The loan facility provides the Company with access to non-dilutive
Business Wire · 10/01 21:30
Geron secures up to $75M non-dilutive financing
Geron (GERN) enters into a loan facility for up to $75M with Hercules Capital (HTGC) and Silicon Valley Bank, available in three tranches through 2022.The facility will be used to support
Seekingalpha · 10/01 20:37
Geron (GERN) Looks Good: Stock Adds 6.5% in Session
Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks · 09/21 13:53
Geron to Present at the H.C. Wainwright Global Investment Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, to be hosted in a virtual format, on Monday
Business Wire · 09/09 14:00
CRM, HPE among premarket gainers
Tyme Technologies (TYME) +29% as oncology research reveals potential new oral therapy TYME-19 in the fight against COVID-19.SCWorx (WORX) +32%.Immunic (IMUX) +20% as Piper goes bargain shopping.Heat Biologics (HTBX) +19%
Seekingalpha · 08/26 12:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GERN. Analyze the recent business situations of Geron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GERN stock price target is 4.000 with a high estimate of 7.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 185
Institutional Holdings: 158.73M
% Owned: 51.13%
Shares Outstanding: 310.47M
TypeInstitutionsShares
Increased
45
14.70M
New
39
82.17M
Decreased
22
1.84M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/President/Chief Executive Officer/Director
John Scarlett
Chief Financial Officer/Executive Vice President - Finance/Treasurer
Olivia Bloom
Chief Operating Officer/Executive Vice President
Andrew Grethlein
Executive Vice President/Secretary
Stephen Rosenfield
Vice President
Israel Gutierrez
Executive Vice President
Anil Kapur
Executive Vice President
Melissa Kelly Behrs
Executive Vice President
Aleksandra Rizo
Lead Director/Independent Director
Karin Eastham
Vice President/Director of Human Resources
Shannon Odam
Independent Director
Dawn Bir
Vice President
Sharo McBain
Independent Director
V. Bryan Lawlis
Vice President - Business Development
Lynn Bodarky
Independent Director
Susan Molineaux
Independent Director
Elizabeth O'Farrell
Independent Director
Robert Spiegel
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GERN
Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat includes IMerge, a Phase II/III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Geron Corporation stock information, including NASDAQ:GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.